Clinical Trial

Vaccination Response Modulation With a Targeted Rapamycin Protocol Study

Study acronym: VON TRAPP
Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated May 14, 2026 (before its estimated July 2026 completion). Its status may not reflect the trial's current state.
Summary
This study will investigate dialysis recipients' responses to important vaccines. Research suggests that a medication commonly used by transplant recipients may improve vaccine responses. The investigators will be conducting a clinical trial to see whether a short course of low-dose Sirolimus improves the response to vaccination against respiratory syncytial virus (RSV) and influenza (flu) in patient with kidney disease over 60 years old who receive haemodialysis.
Trial Details
NCT Number NCT07587801
Lead Sponsor Central Adelaide Local Health Network Incorporated
Conditions Vaccine Immune Response, Haemodialysis Patients, Older Adults
Enrollment 60 participants
Start Date 2026-05
Primary Completion 2026-07 (estimated)
Study Completion 2026-07 (estimated)
Updated on ClinicalTrials.gov 2026-05-14